We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.045 | -2.95% | 1.48 | 1.45 | 1.50 | 1.525 | 1.475 | 1.53 | 4,058,690 | 16:35:28 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.28 | 11.4M |
Date | Subject | Author | Discuss |
---|---|---|---|
17/4/2024 12:59 | They answer questions in these meetings, but not enough. They should show more info how to save money to get through the periods before H2 2025. | qipincha | |
17/4/2024 12:50 | You can not ask any questions it’s staged and they pick the ones they posted themselves it’s a staged farce | best1467 | |
17/4/2024 10:04 | Very difficult to be a big player when your share price is languishing at all time lows and difficult to raise monies without more dilution. A very promising Company years ago, management must take full responsibility for the current debacle | ny boy | |
16/4/2024 07:19 | Results 30 April, when you can ask your Qs. | weatherman | |
15/4/2024 13:38 | Execs and esp CEO (and maybe even NEDS) should take a pay cut they are way above average for the market cap and pocketing a significant chunk of revenue at every other shareholders expense. | cordwainer | |
12/4/2024 16:05 | RI out of the frying pan and into the fire, white board members fail in darkest Africa, it's a pay back for colonialism! TRP is a duffer, always looking for never ending money to finance, just confetti shares how many in issue now, must be 16 Billion + 🤡😂)0 | ny boy | |
11/4/2024 12:16 | Missed a bullet now stood in front of an ak47 with TRPHa ha | bimbamboom | |
10/4/2024 12:33 | Was it a Hardman researh report ?? | riskyinvestor | |
10/4/2024 12:33 | I was going to buy these at 8p last year because of a research report which said they are worth around 50p I missed a bullet Am in Tower Resources (TRP) Where if funds allow I will be topping up every month if it stays at the 0.02p levels | riskyinvestor | |
09/4/2024 22:57 | It was a half decent day until 4 o clock.Next update is crucial and I can't believe we can't exploit this FDA approved drug to create a profitable business and an share price many multiples of the current price.But then wtfdik. | husbod | |
09/4/2024 10:12 | Yes, market size is tiny | qipincha | |
08/4/2024 09:31 | I just bought in my ISA, many sold to realise the tax loss before the end of the tax year. Business Metrics from the latest trading update ! · Cash: $13.9m as of 31 December 2023 · Total 2023 revenue and other income: $17.5m, a 2.8x increase over FY22 o Accrufer® revenue: $11.6m, a 3.1x increase over FY22 o Ex-U.S. revenue: $1.5m o Other income revenue including Viatris milestone payments: $4.4m · U.S. Q4 2023 Revenue: $4.3m · Average net selling price: c.$145/prescription in H2 2023, an increase of c.21% compared with H1 2023 · Total 2023 Prescriptions: c.77k, a 3.1x increase over FY22 The company is making progress and the MCap shouldn’t be at this ridiculously low level. I believe either AOP Health or a pharma company will buy them eventually. | sam_ | |
05/4/2024 18:52 | Forget my last - it was just some stupid link someone gave me to an STX question but wrong company | bolitix | |
05/4/2024 18:26 | Have they now changed to Argent Biofarm Ltd with a new CEO Roby Zomer or am i picking things up wrong | bolitix | |
05/4/2024 08:17 | Same. Long and wrong. Written off the holding. It either goes to 0 with these fools in charge or magically realises it's value by someone else | reviewwworld | |
04/4/2024 18:19 | Now i lost lots to these clowns so have now written that loss off. I did say this CEO would drag this share price near a penny some time ago. Now the worst could well be on the cards if they do a share exchange for the new company on a 1:10, 1:100 or even 1:1000 ratio to hype the price up on a Par so if 1:1000 the share price per share will be increased by a factor of 1000 to compensate but that will immediately drop lower. Hence, stay away from this company until it changes this CEO and its mindset. | bolitix | |
04/4/2024 09:24 | I admit management screwed up big time on admission of data irregularities. Was it Eddie who they pay minimum 60k a year to produce this exergerated phony report? If they provide a good update and dont fool around which they now can not afford to do so, i expect share price to recover as new target numbers are more realistic | razoblade | |
04/4/2024 07:38 | You are assuming they can add up. No one can trust their misleading statements. They knew when previous cfo left.Has Greg got his money out to buy shares. The man's a disgrace. | chester9 | |
03/4/2024 22:56 | the company should be able to manage their finance so long as they do it carefully! there are also other options on the table. but it is wisely to wait until they update their Q1 finance | qipincha | |
03/4/2024 17:20 | Tim was Jeff Bezos compared to Greg the Bozo | reviewwworld | |
03/4/2024 14:51 | GOING BUST GOING BUST GOING BUST GOING BUST GOING BUST GOING BUST | goforgold1 | |
03/4/2024 14:33 | Share price reflects almost unilateral conviction that the CEO (and fellow) management are possibly the most incompetent C-suite currently in employment.In situations like this, as I've said on this board, serve as a reminder that investing is about shareholder return. It doesn't matter if the company has the golden goose if they continuously just fry it's eggs for breakfast | reviewwworld |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions